ANNOUNCEMENT 07 Apr 2020

In April 2020, BARDA announced providing funding to support Grifols in the development of plasma-based treatment for COVID-19.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

U.S. Medical Countermeasures, Newsroom, “HHS, Department of Defense, and Grifols Collaborate to Develop Plasma-based Treatment for COVID-19”. Available at: https://www.medicalcountermeasures.gov/newsroom/2020/grilfols-plasma/

Inception date: 07 Apr 2020 | Removal date: open ended

State aid, unspecified

On 7 April 2020, the Biomedical Advanced Research and Development Authority (BARDA) jointly with the U.S. Department of Defense (DOD) announced providing USD 12.5 million to support Grifols Shared Services North America, Inc. in the development of COVID-19 treatments that use convalescent plasma or hyperimmune globulin.

Convalescent plasma originates from the blood of individuals who have recovered from COVID-19. Antibodies contained in Convalescent plasma can be used against the COVID-19. On the other hand, by concentrating the antibodies, hyperimmune globulin, more uniform therapeutic can be extracted from plasma. Funding from BARDA will help Grifols to test these therapeutics in clinical trials.

This award is funded by HHS’s BARDA as part of the COVID-19 medical countermeasure portfolio. BARDA supports the development of medical countermeasures such as vaccines, drugs, and diagnostics from research to advanced development through public-private partnerships. BARDA’s support includes funding, technical assistance, and other core services. The present announcement didn’t include the type of contribution from BARDA, “state aid, unspecified” is selected as the intervention type.

AFFECTED SECTORS

 

AFFECTED PRODUCTS